Request Info Medical Affairs Prescribing Information Important Safety Information Visit Patient Site

SCIg is supported by a professional CIDP guideline

Learn about the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force–Second Revision.

EAN/PNS* guideline on diagnosis and treatment of CIDP “strongly recommends” SCIg for CIDP maintenance1

treatment flexibility icon

Treatment flexibility

Consider patients’ personal preferences and clinical benefits when choosing SCIg or IVIg1

  • While the guideline does not recommend a preference between IVIg or SCIg for CIDP maintenance, it does support patient preferences
Personalized dosing icon

Personalized dosing

Tailor SCIg dose according to individual treatment response1

  • Clinical study results indicate that there were lower relapse rates in the higher dose group. There is insufficient evidence that a higher dose is superior to a lower dose
  • Therefore, long-term dosing should be individualized and tailored to find the most appropriate dose
*EAN/PNS=European Academy of Neurology/Peripheral Nerve Society.

Watch Dr. Peter Van den Bergh, lead author of the EAN/PNS* guideline, presenting on behalf of the task force

  • Introduction and Task Force (0:00–0:57)
  • CIDP Definition and Diagnosis (0:58–9:33)
  • Induction Treatment Recommendations (9:34–10:40)
  • Maintenance Treatment Recommendations (10:41–12:25)
Access the EAN/PNS* guideline PDF

Dosing

Explore tools and information to help you tailor treatment to individual patient needs

Dosing calculator

Administration

Explore volumes, rates, and other information to help your patients self-administer Hizentra

Administration guidance
Reference: 1. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Eur J Neurol. 2021;1‐28. https://doi.org/10.1111/ene.14959.
acuity
You are now leaving the current website.

Do you want to continue?

No Yes